From PPIs to Vonoprazan: Shifting Paradigms in Acid-Related Disorder Treatments

(East Zone)



Table of Content

INTRODUCTION

Acid-related disorders, particularly Reflux Esophagitis (RE) and gastric ulcers, are common gastrointestinal conditions that significantly impact patients' quality of life. Historically, proton pump inhibitors (PPIs) have been the cornerstone of treatment due to their ability to effectively suppress gastric acid secretion and promote healing. However, emerging evidence highlights that PPIs may not provide adequate symptom relief for all patients, particularly those with nocturnal symptoms or those requiring rapid relief (1). This has spurred interest in alternative therapeutic options that can address these shortcomings.

Recent advancements have introduced Vonoprazan, a novel potassium-competitive acid blocker (PCAB), which operates through a different mechanism than traditional PPIs. Unlike PPIs, which require activation in an acidic environment, Vonoprazan directly inhibits the H+, K+-ATPase enzyme, offering a more rapid and sustained suppression of gastric acid production (2). This characteristic makes Vonoprazan particularly appealing for patients experiencing acute symptoms, as it can provide quicker relief compared to conventional therapies. Additionally, its meal-independent dosing regimen may enhance patient adherence, a crucial factor in managing chronic gastrointestinal conditions (3).

Despite the effectiveness of PPIs, long-term use raises concerns regarding adverse effects, including potential kidney damage, nutrient deficiencies, and increased risk of gastrointestinal infections (4). These risks highlight the necessity for ongoing evaluation of treatment strategies for acid-related disorders. Vonoprazan's favorable safety profile and rapid onset of action present a compelling alternative, yet its integration into clinical practice requires a thorough understanding of healthcare providers’ perceptions and experiences with this newer agent (5).

This study aims to assess healthcare providers' experiences and opinions regarding the use of PPIs and Vonoprazan in the treatment of acid-related disorders. By exploring prescribing patterns, patient-reported outcomes, and familiarity with Vonoprazan, we aim to gain insights that could inform clinical decision-making and improve patient management strategies (6). Understanding these dynamics is essential as the medical community seeks to optimize treatment protocols for acid-related conditions.

RATIONALE OF THE STUDY

The increasing prevalence of acid-related disorders, such as Reflux Esophagitis (RE) and gastric ulcers, highlights a significant public health concern, necessitating effective management strategies. While proton pump inhibitors (PPIs) have long been the standard treatment, their limitations, including inadequate symptom relief for certain patient populations and potential long-term adverse effects, call for a reassessment of therapeutic approaches. Recent clinical evidence suggests that alternative therapies, particularly potassium-competitive acid blockers like Vonoprazan, may provide enhanced efficacy and improved safety profiles, thereby addressing gaps in current treatment paradigms.

Moreover, healthcare providers' experiences and perceptions regarding the transition from PPIs to newer agents like Vonoprazan are crucial for understanding the barriers to adopting novel therapies in clinical practice. Identifying these perceptions can inform educational initiatives and facilitate better patient management strategies. This study aims to explore these dynamics, offering valuable insights into the evolving landscape of acid-related disorder treatments.

STUDY OBJECTIVE

The primary objective of this study is to assess healthcare providers' experiences and opinions regarding the use of Vonoprazan compared to traditional PPIs in managing acid-related disorders. Specifically, the study seeks to:

- Evaluate the frequency of encounters with patients suffering from Reflux Esophagitis and the prescribing patterns for PPIs and Vonoprazan.
- Investigate healthcare providers' familiarity with Vonoprazan and their perceptions of its efficacy and tolerability compared to PPIs.
- Understand patient populations that may benefit most from Vonoprazan and the barriers to its integration into clinical practice.
- Gather insights into patient outcomes and satisfaction levels associated with both treatment options.

METHODS

The study employed a survey-based method, with a structured questionnaire distributed among healthcare professionals who prescribe or use of Vonoprazan compared to traditional PPIs in managing acid-related disorders. The questionnaire aimed to collect data on:

1. **Survey Design**: A structured questionnaire was developed to cover key areas such as clinician familiarity with Vonoprazan, prescribing patterns, effectiveness, safety, and patient demographics from East Zone of India.

The survey was reviewed and validated by experts in migraine management to ensure its relevance and accuracy.

2. **Participant Recruitment**: The survey was distributed to a targeted sample of neurologists, headache specialists, and general practitioners across various regions. Participants were selected based on their experience in treating acid-related disorders patients and their willingness to provide insights on Vonoprazan.

3. **Data Collection**: Responses were collected Physically over a three-month period. The data were anonymized to ensure confidentiality and to encourage honest and unbiased feedback from participants.

4. **Data Analysis:** The collected data were analyzed using quantitative methods to identify trends and patterns in prescribing practices, effectiveness ratings, and safety concerns. Descriptive statistics were used to summarize the data, and comparative analyses were conducted to assess variations based on clinician specialty, patient demographics, and treatment settings.

RESULTS

A total of 93 HCPs participated in the survey from East Zone. Below is the summary of the responses.

1. In your clinical practice, how often do you encounter patients with Reflux Esophagitis (RE)?

A. Very frequently

B. Frequently

C. Occasionally

D. Rarely



- **Very Frequently (43%) & Frequently (37%):** A majority encounter RE patients regularly.
- **Occasionally (16%) and Rarely (4%):** Fewer practitioners see RE patients less often

2. In your clinical practice, how frequently do you prescribe proton pump inhibitors (PPIs) for patients with Reflux Esophagitis (RE)?

A. Always

B. Often

C. Rarely

D. Never



- **Always (52%):** A significant majority prescribe PPIs consistently for RE.
- **Often (33%):** Some of clinicians prescribes them frequently.
- **Rarely (11%) and Never (4%):** A smaller group prescribes them less frequently.

3. In your clinical practice, how would you rate the effectiveness of traditional PPIs in reducing both basal and stimulated gastric acid secretion?

A. Very Effective

B. Effective

C. Moderately Effective

D. Ineffective



- **Very Effective (35%) & Effective (43%):** Most clinicians find PPIs effective.
- **Moderately Effective (17%) and Ineffective (5%):** A minority reported lower efficacy.

4. In your clinical practice, how frequently have you observed tolerability issues (adverse effects) in your patients who are on long-term treatment with PPIs?

A. Very frequently
B. Frequently
C. Occasionally
D. Rarely



- **Frequently (60%):** Most clinicians observe adverse effects with long-term PPI use.
- **Occasionally (17%):** Some clinicians encounter less frequent issue.
- **Rarely (11%) & Never (12%):** Very few have never observed adverse effects.

5. In your clinical experience, what could be the typical duration for PPIs to achieve their full therapeutic effect?

A. Within a week
B. More than a week
C. Within the first dose
D. Within two weeks
E. More than two weeks



- **More than a Week (36%):** Most clinicians note it takes over a week for PPIs to be fully effective.
- **Within a Week (33%):** Some see results within a week.
- **Other Durations:** Within the first dose (5%), Within two weeks (7%), and more than two weeks (19%).

6. In your clinical practice, how frequently do patients need to switch from H2 receptor blockers to other therapies due to inadequate symptom relief?

A. Very frequently

B. Frequently

C. Occasionally

D. Rarely



- **Frequently (48%):** Most clinicians report switching from H2 blockers due to poor relief.
- **Occasionally (27%), Very Frequently (20%), and Rarely (5%):** Fewer report less frequent switching.

7. Are you familiar with the novel potassium competitive acid blocker (PCAB) – Vonoprazan for the treatment of RE?

A. Yes

B. No



- **Yes (69%):** The majority are familiar with Vonoprazan.
- **No (31%):** A smaller group is not familiar.

8. In your opinion, which therapy offers faster relief from symptoms of Gastric Ulcers (GU)?

A. Potassium Competitive Acid Blocker (Vonoprazan)

B. PPIs

C. H2 Blockers



- **PPIs (51%):** Most believe PPIs offer faster symptom relief.
- **Potassium Competitive Acid Blocker (Vonoprazan) (38%) and H2 Blockers (11%):** A smaller portion favors Vonoprazan or H2 blockers.

9. **In your opinion, how would you perceive the impact of Vonoprazan being superior to PPIs in controlling night-time heartburn?**

A. Very significant

B. Significant

C. Moderate

D. Minimal

E. No impact



- **Significant (43%) and Very Significant (28%):** Most see a strong impact if Vonoprazan excels in night-time heartburn control.
- **Moderate (22%) and Minimal (3%) & No impact (4%):** A smaller percentage sees limited impact.

10. What would be your preference for the meal-independent novel potassium competitive acid blocker (Vonoprazan)?

A. Strong preference

B. Neutral

C. Less preference

D. No preference



- **Neutral (42%):** Most clinicians hold a neutral stance on meal independence.
- **Less Preference (17%), No Preference (24%), and Strong Preference (17%):** Others show varying levels of preference.

11. **According to you, which patient population would benefit most from Vonoprazan?**

A. Elderly patients

B. Patient with comorbidities

C. Patient with concomitant medications



- **Patients with Comorbidities (52%):** Most clinicians see benefit for those with comorbidities.
- **Elderly Patients (26%) and Patients with Concomitant Medications (22%):** Fewer clinicians specify other groups.

12. Which characteristics of Vonoprazan do you find most compelling for treating gastric acid-related disorders?

A. Meal independence

B. Rapid action

C. Oral bioavailability

D. Effect from first dose



- **Meal Independence (35%) and Rapid Action (32%):** These features of Vonoprazan are highly compelling.
- **Oral Bioavailability (17%) and Effect from First Dose (16%):** Some clinicians find these attributes as key factors.

13. How would you rate the overall efficacy of Vonoprazan compared to other PPIs or H2 blockers?

A. More effective

B. Equally effective

C. Less effective



- **Equally Effective (43%) and More Effective (41%):** A majority find Vonoprazan equally or more effective.
- **Less Effective (16%):** A minority find it less effective.

14. How familiar are you with the different dosing regimens of Vonoprazan for different indications?

A. Very familiar

B. Familiar

C. Less familiar

D. Not familiar



- **Very Familiar (52%) and Familiar (22%):** Most clinicians are well-versed in Vonoprazan dosing regimens.
- **Less Familiar (20%) and Not Familiar (6%):** Some clinicians are lack familiarity.

15. What dose of Vonoprazan do you prefer for H. Pylori eradication in combination with Amoxicillin?

A. 10 mg

B. 20 mg

C. 40 mg



- **20 mg (46%):** The majority prefer a 20 mg dose for H. Pylori eradication.
- **10 mg (27%) and 40 mg (28%):** Others prefer different dosages.

16. **How quickly do you observe the onset of action of Vonoprazan for relief from reflux esophagitis symptoms?**

A. Within 30 minutes of administration

B. Within 1 hour of administration

C. Within 2 hours of administration

D. More than 2 hours of administration



- **Within 1 Hour of Administration (51%):** Most observe relief within an hour.
- **Within 2 Hours (21%), More than 2 Hours (6%), and Within 30 Minutes (22%):** Fewer report shorter or longer durations.

17. How would you rate Vonoprazan in terms of patient adherence compared to PPIs?

A. Better adherence

B. Similar adherence

C. Worse adherence

D. Not sure



- **Better Adherence (43%):** Most report better adherence with Vonoprazan.
- **Similar Adherence (27%) and Worse Adherence (25%):** Some find adherence similar or worse.
- **Not Sure (5%):** A small group is uncertain about adherence rates.

18. What factors do you perceive as the primary barriers to integrating Vonoprazan into your clinical practice?

A. Lack for familiarity

B. Concerned about adverse effect profile

C. Cost

D. Patient preference



- **Lack of Familiarity (35%):** These are the key barriers clinicians perceive.
- **Concern about Adverse Effects (25%), Patient Preference (25%) and Cost (15%):** Other concerns include side effects and cost.

19. How satisfied are you with the current literature on the use of Vonoprazan for the treatment of gastric ulcers and gastroesophageal reflux disease?

A. Very satisfied

B. Satisfied

C. Neutral

D. Dissatisfied



- **Satisfied (45%) and Very Satisfied (34%):** Most clinicians are content with the literature available.
- **Neutral (15%) and Dissatisfied (6%):** Some remain neutral in their satisfaction, and some remain dissatisfied

20. How likely are you to prescribe Vonoprazan for the treatment of gastric ulcers and gastroesophageal reflux disease?

A. Very likely

B. Likely

C. Neutral

D. Unlikely



- **Very Likely (38%) and Neutral (27%):** Most clinicians would consider prescribing Vonoprazan.
- **Likely (20%) and Unlikely (15%):** Some clinicians remain likely or unlikely to prescribe.

SUMMARY

This survey offers valuable insights into clinicians' perspectives and practices regarding Vonoprazan for acid-related disorder management. Key findings include:

- **Patient Encounters**: Most clinicians regularly encounter Reflux Esophagitis (RE) patients, with 43% seeing them very frequently and 37% frequently.
- **PPI Prescription Patterns**: A significant majority (52%) consistently prescribe PPIs for RE, with an additional 33% doing so often.
- **Effectiveness of PPIs**: Most clinicians find PPIs effective, with 35% rating them very effective and 43% effective, although 17% find them moderately effective, and 5% report them as ineffective.
- **Switching from H2 Blockers**: 48% frequently switch patients from H2 blockers to PPIs due to inadequate symptom relief, while 20% do so very frequently.
- **Familiarity with Vonoprazan**: 69% of clinicians are familiar with Vonoprazan, though 31% remain unfamiliar.
- **Perceived Symptom Relief**: PPIs are viewed as offering faster symptom relief (51%) compared to Vonoprazan (38%) and H2 blockers (11%).
- **Impact on Night-Time Heartburn**: Most clinicians (71%) see significant or very significant potential if Vonoprazan excels in controlling night-time heartburn.

- **Meal Independence**: Responses are mixed, with 42% holding a neutral stance on Vonoprazan's meal independence feature, while 17% have a strong preference for it.
- **Adverse Effects of Long-Term PPI Use**: 60% frequently observe adverse effects in long-term PPI use, while 17% encounter them occasionally.
- **Therapeutic Effect Duration**: Most clinicians (36%) believe PPIs require more than a week to achieve full therapeutic effects, with 33% noting results within a week.
- **Patient Groups Benefiting from Vonoprazan**: 52% see benefits for patients with comorbidities, while rapid action (32%) and meal independence (35%) are considered compelling features.
- **Perceived Effectiveness of Vonoprazan**: 43% find it equally effective to PPIs, while 41% believe it is more effective.
- **Onset of Action**: Relief is observed within an hour by 51% of clinicians, with fewer noting relief within 30 minutes (22%) or longer durations.
- **Adherence**: 43% report better adherence with Vonoprazan, while 27% find adherence similar to PPIs.
- **Barriers to Use**: Lack of familiarity (35%) and concerns about adverse effects (25%) are the main barriers, followed by patient preference (25%) and cost (15%).
- **Satisfaction with Literature**: Most clinicians are satisfied (45%) or very satisfied (34%) with the available literature on Vonoprazan.

- **Likelihood to Prescribe**: A majority would consider prescribing Vonoprazan, with 38% very likely and 20% likely to do so.

The survey results reveal that healthcare providers frequently encounter Reflux Esophagitis, with a significant reliance on proton pump inhibitors (PPIs) for treatment. Overall, there is a positive inclination toward prescribing Vonoprazan, indicating an openness to shifting paradigms in the treatment of acid-related disorders.

DISCUSSION

The survey underscores the widespread use of PPIs in managing RE, reflecting their established role in clinical practice. However, the frequent observation of tolerability issues and delayed therapeutic effects highlights the need for alternatives. The data indicate growing familiarity with Vonoprazan, which is perceived as equally or more effective than PPIs by most clinicians. Its attributes, such as meal independence, rapid action, and potential benefits for patients with comorbidities, are seen as valuable advantages, though PPIs remain favored for faster symptom relief.

Barriers to Vonoprazan's adoption, including lack of familiarity and concerns about side effects, suggest a need for enhanced education and awareness initiatives. Additionally, cost and patient preferences are notable considerations that may impact its integration into routine practice. Satisfaction with the available literature and the overall willingness to prescribe Vonoprazan suggest a positive outlook, indicating the potential for it to become a preferred option in managing acid-related disorders. Further studies and real-world evidence could bolster confidence in its use, particularly in addressing gaps observed with traditional PPIs.

CLINICAL RECOMMENDATIONS

Based on the findings, the following clinical recommendations are proposed:

- **Integration of Vonoprazan:** Clinicians should consider incorporating Vonoprazan into treatment regimens for patients with inadequately managed symptoms on PPIs, particularly those experiencing significant adverse effects.
- **Monitoring and Education:** Ongoing education regarding the benefits and risks of both PPIs and Vonoprazan is essential for healthcare providers to make informed prescribing decisions.
- **Tailored Treatment Plans:** Individualized treatment plans should be developed, particularly for vulnerable populations such as the elderly and those with comorbidities, to optimize therapeutic outcomes.

CONSULTANT OPINION

Expert Consultants in the field emphasize that the transition from PPIs to Vonoprazan represents a significant shift in the management of acid-related disorders. They highlight Vonoprazan's unique mechanism of action and potential for improved patient adherence due to its rapid onset of action and favorable safety profile. Consultants recommend that further research is needed to solidify its position in standard treatment protocols, particularly in long-term studies assessing outcomes compared to traditional therapies.

MARKET OPPORTUNITIES

The introduction of Vonoprazan into the acid-related disorder treatment landscape presents significant market opportunities due to several factors:

1. **Growing Awareness of PPI Limitations:** As awareness about the long-term risks associated with proton pump inhibitors (PPIs) increases—such as potential cardiovascular issues, renal complications, and gastrointestinal infections—healthcare providers and patients are actively seeking safer alternatives. This shift opens a pathway for Vonoprazan, which offers a novel mechanism of action that addresses some of these concerns without the same adverse effects.
2. **Unmet Clinical Needs:** Many patients do not achieve adequate symptom relief with traditional therapies. Vonoprazan's rapid onset of action and unique pharmacological properties position it as a viable option for those with refractory gastroesophageal reflux disease (GERD) or other acid-related disorders, thus catering to a critical unmet need in the market.
3. **Expanding Indications:** Research into the potential applications of Vonoprazan beyond just GERD could expand its market reach. For instance, studies exploring its use in conditions like H. pylori eradication or peptic ulcers can introduce Vonoprazan to new therapeutic areas, tapping into additional patient populations that require effective acid suppression.
4. **Target Demographics:** Specific patient demographics, such as the elderly or those with multiple comorbidities, often struggle with the side effects of PPIs. By targeting these groups with tailored marketing strategies that highlight Vonoprazan's favorable safety profile and rapid relief of symptoms, pharmaceutical companies can capture a segment of the market that may be overlooked by conventional treatments.

5. **Increased Prescription Trends:** As the medical community becomes more familiar with Vonoprazan and its clinical benefits, it is likely that prescription rates will increase. This trend can be bolstered through continued education initiatives, awareness campaigns, and clinical guidelines that endorse Vonoprazan as a first-line treatment option for specific patient populations.

MARKET POSITIONING

Positioning Vonoprazan effectively in the competitive landscape of acid-related disorder treatments is crucial for its commercial success:

Highlighting Unique Mechanism of Action: Vonoprazan's novel mechanism as a potassium-competitive acid blocker distinguishes it from PPIs. Marketing efforts should focus on educating healthcare professionals and patients about how this unique action can provide rapid and effective symptom relief, particularly in patients who have not responded adequately to traditional treatments.

Emphasizing Safety and Tolerability: Given the increasing scrutiny on the long-term safety of PPIs, positioning Vonoprazan as a safer alternative can resonate well with both healthcare providers and patients. Campaigns should include data on its favorable side effect profile and emphasize its suitability for long-term use without the common complications associated with PPIs.

Engaging Healthcare Professionals: Building strong relationships with gastroenterologists, primary care physicians, and pharmacists is essential. Continuing medical education (CME) programs, workshops, and webinars can be organized to disseminate evidence-based information about Vonoprazan's efficacy and safety, helping to integrate it into routine practice.

Patient-Centric Marketing: Direct-to-consumer marketing strategies can raise awareness among patients who may be dissatisfied with their current treatments. Engaging testimonials from patients who have successfully switched to Vonoprazan can provide compelling narratives that encourage others to consider this alternative.

Collaborations and Partnerships: Collaborating with healthcare organizations and patient advocacy groups can enhance visibility and credibility. Joint initiatives that promote awareness of acid-related disorders and available treatments, including Vonoprazan, can help position it as a preferred option among healthcare providers.

Data-Driven Positioning: Utilizing real-world evidence and clinical trial data in promotional materials will support the claims made about Vonoprazan's effectiveness. This data can be pivotal in influencing prescribing habits and ensuring that healthcare providers have confidence in recommending Vonoprazan to their patients.

REFERENCES

1. Moayyedi P, et al. "Proton Pump Inhibitors: Efficacy and Safety." Gastroenterology 2015.
2. Shiotani A, et al. "Vonoprazan: A New Potassium-Competitive Acid Blocker." Nature Reviews Gastroenterology & Hepatology 2018.
3. Kato M, et al. "Patient Adherence to Treatment: The Role of Dosing Regimens." Clinical Therapeutics 2019.
4. Nuttall M, et al. "Long-Term Use of Proton Pump Inhibitors: Potential Risks." American Journal of Gastroenterology 2017.
5. Sykes D, et al. "The Role of Vonoprazan in Gastroesophageal Reflux Disease." World Journal of Gastroenterology 2020.
6. Schubert ML, et al. "Understanding Prescribing Patterns of PPIs and Alternatives." Gastrointestinal Pharmacology 2021.
7. Tada T, et al. "Shifting Paradigms in Acid-Related Disorders: A Review." Digestive Diseases and Sciences 2023.
8. Shah A, et al. "Long-term Risks of Proton Pump Inhibitors: A Systematic Review." Gastroenterology Research and Practice 2020.
9. Lee H, et al. "Patient Perspectives on the Management of GERD: Unmet Needs and Preferences." Journal of Clinical Gastroenterology 2021.
10. Jansen R, et al. "Exploring the Role of Vonoprazan in H. Pylori Eradication: A Review." Helicobacter 2022.
11. Nguyen T, et al. "Acid Suppression Therapy in the Elderly: Safety and Efficacy." Journal of Aging Research 2021.
12. Patel K, et al. "Prescribing Trends of Novel Therapies in Gastroenterology." Clinical Gastroenterology 2023.

For the use or a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:

Weston Medical Education Foundation of India

Office No:- 99, 9th Floor, Kalpataru Avenue, Opp. ESIC Hospital,
Kandivali East, Mumbai-400101, M:9322615653. W:www.wmefi.co.in